The Helmholtz Association is kicking off 2026 with new research initiatives on strategic future topics to bring technological breakthroughs into practical application more quickly. The Helmholtz initiatives “Biomedical...
For decades, tuberculosis (TB) has been one of the deadliest infectious diseases worldwide. Resistant strains of Mycobacterium tuberculosis are particularly problematic, as many established drugs are becoming...
Two collaborative projects involving the Helmholtz Centre for Infection Research (HZI) are being funded with 100,000 euros each from the joint program "zukunft.niedersachsen" of the state of Lower Saxony and the...
The global skin care company Beiersdorf and the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) have entered into a long-term, exclusive partnership. In this collaboration they aim to investigate the...
Prof. Rolf Müller, Scientific Director of the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and Head of the Research Unit “Novel Antibiotics” at the German Center for Infection Research (DZIF), has...
The CRISPR “gene scissors” have become an important basis for genome-editing technologies in many fields, ranging from biology and medicine to agriculture and industry. A team from the Helmholtz Institute for RNA-based...
The gene scissors CRISPR-Cas are an important tool for genome editing. However, their functionality is limited because they rely on specific sequences to operate. Their ancient ancestors, on the other hand, may have...
Rare diseases affecting fewer than five in 10,000 people are often particularly difficult to diagnose and treat. As part of their joint funding program “zukunft.niedersachsen”, the state of Lower Saxony and the...
Experts are increasingly turning to machine learning to predict antibiotic resistance in pathogens. With its help, resistance mechanisms can be identified based on a pathogen’s genetics. However, the results should be...
